Slingshot members are tracking this event:

Celgene discontinues GED-0301 (mongersen) Inflammatory Bowel Disease Program's phase III REVOLVE trial (CD-002) and the extension trial (SUSTAIN, CD-004)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details
At this time, the phase III DEFINE trial (CD-003) in Crohn's disease will not be initiated. Celgene is waiting to review the full dataset from the phase II trial with GED-0301 in ulcerative colitis (UC) to determine next steps.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 19, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Ged-0301, Mongersen, Inflammatory Bowel Disease, Revolve Trial, Cd-002, Sustain, Cd-004